Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Trial Profile

Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2018 Planned initiation date (estimated date of first paticipant enrollment) changed from 2 Nov 2018 to 20 Nov 2018.
    • 27 Oct 2018 Planned initiation date (estimated date of first paticipant enrollment) changed from 31 Oct 2018 to 2 november 2018.
    • 23 Oct 2018 Planned initiation date (estimated date of first paticipant enrollment) changed from 2 Oct 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top